Skip to main content
Clinical Trials/NCT00696358
NCT00696358CompletedPhase 3

Comparative Study of 308nm Excimer Lamp and 308nm Excimer Laser in the Treatment of Vitiligo

Centre Hospitalier Universitaire de Nice1 site in 1 countryStarted: March 17, 2009Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 3
Status
Completed
Locations
1
Primary Endpoint
Repigmentation rate in the treated areas

Study Overview

Brief Summary

308 nm excimer lamp and 308 nm excimer laser have both provide interesting results in treating vitiligo. They have the same wavelength but the type of emission of the photons is different. To date there is no direct comparative data concerning these two devices in this indication.

The aim of the study is to make an intra-individual prospective comparison between these two phototherapies.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • patient above 18
  • vitiligo for more than 3 months
  • at least 2 vitiligo symmetric patches more than 10cm²
  • to read and understand the inform consent
  • to have a social security number
  • non pregnant for women

Exclusion Criteria

  • pregnant women
  • history of radiotherapy or skin cancer in the treated areas
  • treatment for vitiligo in the past 4 weeks
  • phototherapy in the past 12 weeks; history of photodermatosis
  • treatment inducing photosensibilization
  • immunosuppression
  • patient who participated in a study in the past 3 months

Arms & Interventions

A

Active Comparator

308 nm excimer lamp

Intervention: 308nm excimer lamp (Radiation)

B

Active Comparator

308 nm excimer laser

Intervention: 308nm excimer laser (Radiation)

Outcomes

Primary Outcomes

Repigmentation rate in the treated areas

Time Frame: 12 weeks

Secondary Outcomes

  • Tolerance and safety of the treatments(12 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials